Zurcher Kantonalbank Zurich Cantonalbank Buys 1,967 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 28.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 8,841 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,967 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Collegium Pharmaceutical were worth $272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in COLL. Everence Capital Management Inc. acquired a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $302,000. Cornercap Investment Counsel Inc. increased its stake in Collegium Pharmaceutical by 4.6% during the 4th quarter. Cornercap Investment Counsel Inc. now owns 22,002 shares of the specialty pharmaceutical company’s stock valued at $677,000 after purchasing an additional 959 shares in the last quarter. Louisiana State Employees Retirement System bought a new stake in Collegium Pharmaceutical during the 4th quarter valued at $502,000. Allspring Global Investments Holdings LLC raised its holdings in Collegium Pharmaceutical by 10.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 45,862 shares of the specialty pharmaceutical company’s stock worth $1,412,000 after buying an additional 4,192 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Collegium Pharmaceutical by 5.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,713 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 868 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock opened at $37.51 on Monday. The business’s fifty day simple moving average is $37.56 and its 200 day simple moving average is $31.91. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical, Inc. has a 12 month low of $20.83 and a 12 month high of $40.95. The firm has a market capitalization of $1.23 billion, a P/E ratio of 31.79 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. The company had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. As a group, analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current year.

Wall Street Analysts Forecast Growth

COLL has been the subject of several recent research reports. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Needham & Company LLC restated a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Piper Sandler reaffirmed an “overweight” rating and set a $39.00 price objective (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, Truist Financial increased their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $39.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.